摘要
目的探讨双歧杆菌四联活菌片联合美沙拉嗪治疗溃疡性结肠炎(UC)患者的效果。方法选取2016年1月~2019年3月我院收治的86例UC患者作为研究对象,按照随机数字表法分为对照组(n=43)和观察组(n=43)。对照组采用美沙拉嗪肠溶片口服治疗,观察组采用美沙拉嗪肠溶片联合双歧杆菌四联活菌片治疗;两组均连续服药2个月。比较两组的治疗有效率、C反应蛋白(CRP)、白介素4(IL-4)、白介素8(IL-8)指标、疾病活动性指数(Mayo)评分及不良反应发生情况。结果治疗2个月后,观察组治疗有效率(95.35%)高于对照组(79.07%),差异有统计学意义(P<0.05);IL-4为(1.38±0.28)ng/ml,高于对照组的(0.94±0.31)ng/ml,CRP为(7.85±2.74)mg/L、IL-8为(17.64±4.59)μg/L,低于对照组的(13.68±3.62)mg/L、(25.54±5.87)μg/L,差异有统计学意义(P<0.05);Mayo评分为(3.42±0.44)分,低于对照组的(5.84±0.38)分,差异有统计学意义(P<0.05);不良反应总发生率(6.98%)低于对照组(25.58%),差异有统计学意义(P<0.05)。结论双歧杆菌四联活菌片联合美沙拉嗪能有效治疗UC,具有协同治疗作用,可提高治疗有效率,调节患者CRP、IL-4、IL-8水平,改善机体免疫功能,减少不良反应的发生,安全性较高,临床应用前景良好,值得推广。
Objective To investigate the effect of Bifidobacterium Quadruple Live Tablets combined with Mesalazine on serum C-reactive protein(CRP) levels and adverse reactions in patients with ulcerative colitis(UC). Methods Eightysix patients with UC admitted to our hospital from January 2016 to September 2019 were enrolled in the study. They were divided into control group and observation group according to the random number table method, 43 cases in each group. The control group was treated with Mesalazine Enteric-Coated Tablets orally;the observation group was treated with Mesalazine Enteric-Coated Tablets and Bifidobacterium Quadruple Live Tablets;the patients in both groups were given continuous medication for 2 months. The treatment efficiency, c-reactive protein(CRP), interleukin-4(IL-4), interleukin-8(IL-8) index, disease activity index(Mayo) score, and adverse reactions were compared between the two groups. Results After 2 months of treatment, the effective rate of treatment in the observation group(95.35%) was higher than that in the control group(79.07%), and IL-4(1.38 ±0.28) ng/ml was higher than that the control group for(0.94±0.31) ng/ml, CRP(7.85±2.74) mg/L, IL-8 index(17.64±4.59) μg/L, were lower than those of the control group(13.68±3.62) mg/L,(25.54±5.87) μg/L, Mayo score(3.42±0.44), and adverse reaction rate(6.98%) were lower than that in the control group for(5.84±0.38), the tatal of incidence of aduorse reactions(6.98%) was lower than that of the control group(25.58%), the differences were statistically significant(P<0.05). Conclusion Bifidobacterium Quadruple Live Tablets combined with Mesalazine can effectively treat UC. It has synergistic therapeutic effect, can improve the treatment efficiency, regulate the levels of CRP, IL-4 and IL-8, and improve the immune function of the body, reducing the occurrence of adverse reactions, high safety, and huge prospects for clinical application, it is worth promoting.
作者
侯静
朱美玲
李运红
HOU Jing;ZHU Mei-ling;LI Yun-hong(Department of Gastroenterology,Nanjing Gulou Hospital Group Suqian People′s Hospital,Jiangsu Province,Suqian223800,China)
出处
《中国当代医药》
2020年第11期59-62,共4页
China Modern Medicine
关键词
溃疡性结肠炎
双歧杆菌四联活菌片
美沙拉嗪
C反应蛋白
不良反应
Ulcerative colitis
Bifidobacterium Quadruple Live Bacteria Tablets
Mesalazine
C-reactive protein
Adverse reactions
